Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling be­hind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecen­triq with a grow­ing ex­per­tise in lung can­cer. The drug will now take an ear­ly lead in the sought-af­ter ad­ju­vant set­ting — but com­peti­tors are on the way.

The FDA on Fri­day ap­proved Tecen­triq as an ad­ju­vant ther­a­py for pa­tients with Stage II-II­IA non small cell lung can­cer with PD-(L)1 scores greater than or equal to 1, mak­ing it the first drug of its kind ap­proved in an ear­ly set­ting that cov­ers around 40% of all NSCLC pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER